Tango Therapeutics, Inc.
TNGX
Jodie situation report
Tango Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 26 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 12 directly disclosed connections are confirming.
- G&A stock-based compensation rose to $6,923 (thousands) in Q1 2026 from $3,269 in Q1 2025, primarily due to modification of previously issued equity awards.
Invalidation: The isolated read changes if TNGX's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind TNGX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
GILDGilead Sciences, Inc.partnerMay 13, 2026 ▾
“The Company’s revenues are primarily generated through its license and collaboration agreement with Gilead.”
RVMDRevolution Medicines, Inc.partnerMay 13, 2026 ▾
“Clinical Trial Collaboration and Supply Agreements In November 2024, the Company and Revolution Medicines, Inc.”
Depended on by
RVMDRevolution Medicines, Inc.partnerMay 6, 2026 ▾
“Tango Collaboration 80 In November 2024, we entered into a clinical collaboration with Tango Therapeutics, Inc.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TNGX is currently a Follower in the organic co-movement group High-Beta Risk-On. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.